There are 383 resources available
177P - Feasibility and usefulness of evaluation of immune status of lung cancer patients by EBUS/TBNA cells analysis
Presenter: Joanna Domagala-Kulawik
Session: Poster Display session
178P - Germline genetic variants associated with different premalignant lesions in the bronchial epithelium
Presenter: Tatiana Gerashchenko
Session: Poster Display session
179P - Clinical profile of SMARCA4/SMARCB1-mutated non-small cell lung carcinomas: A retrospective study in a Spanish institution
Presenter: Gonzalo Fernandez
Session: Poster Display session
180P - Schwann cells promotes tumour progression in small cell lung cancer
Presenter: Sophie cao
Session: Poster Display session
181P - Anlotinib enhances the antitumor activity of high‑dose irradiation combined with anti‑PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer
Presenter: Meng Yuan
Session: Poster Display session
182P - Therapeutic activity of thiostrepton in patient-derived malignant pleural effusions
Presenter: Brian Cunniff
Session: Poster Display session
79TiP - A Phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Presenter: Frans Opdam
Session: Poster Display session
71P - Predictors of anxiety and depression among advanced lung cancer patients attending palliative care department: An experience from the rural cancer centre
Presenter: Chaitanya Patil
Session: Poster Display session
84P - SHR-1316 vs placebo in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: A randomized, double-blind, multicenter, phase 1b/3 trial
Presenter: Yi-Long Wu
Session: Poster Display session
85P - Adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis
Presenter: wang jie
Session: Poster Display session